A study conducted in 2009 involving 13 patients with psoriasis induced by TNFi drugs found that there was a higher expression of CXCL9 in the epidermis of psoriasiform lesions than in healthy control skin and psoriasis patients. This evidence concerns the gene CXCL9 and psoriasis.